Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters











Publication year range
1.
Jt Dis Relat Surg ; 34(2): 338-345, 2023 Apr 26.
Article in English | MEDLINE | ID: mdl-37462637

ABSTRACT

OBJECTIVES: This study aims to investigate the effect of adjuvant cryotherapy added to well-performed high-speed burr curettage on the long-term surgical outcomes of chondroblastoma cases. PATIENTS AND METHODS: Between January 2004 and December 2020, a total of 30 chondroblastoma cases (19 males, 11 females; median age: 18.6 years; range, 9 to 53 years) who were surgically treated were retrospectively analyzed. The pressurized-spray technique was performed using liquid nitrogen. Data including age, sex, radiological appearance, treatment modality, duration of follow-up, skin problems, and recurrence were recorded. All patients received adjuvant liquid nitrogen cryotherapy after extended intralesional curettage with high-speed burr. The bone cavity was filled with an autologous iliac crest bone graft, allograft, or polymethylmethacrylate (PMMA). RESULTS: The median follow-up was 54 (range, 19 to 120) months. The lesion was located around the knee in 16 (53.3%), in the shoulder in seven (23.3%), around the hip in five (16.6%), and in the ankle in two (6.6%) cases. The defect was filled with an autologous iliac crest bone graft in 28 (93.3%), an additional allograft in eight (26.7%), and PMMA in two (6.7%) cases. Local recurrence was observed in only two (6.7%) patients during follow-up. Two (6.7%) patients developed physeal growth arrest. Osteoarthritic changes were observed in two (6.7%) patients (one knee and one hip) due to the periarticular location of the tumor. Three (10%) patients had skin complications. None of the cases had a pathological fracture. CONCLUSION: A well-performed extended intralesional curettage with high-speed burr is the first and essential step in treating chondroblastoma. Adding adjuvant liquid nitrogen cryotherapy with high-speed burr can improve treatment outcomes and significantly reduce the recurrence rate of this disease.


Subject(s)
Bone Neoplasms , Chondroblastoma , Male , Female , Humans , Adolescent , Chondroblastoma/surgery , Chondroblastoma/etiology , Retrospective Studies , Polymethyl Methacrylate , Cryotherapy/adverse effects , Curettage/adverse effects , Curettage/methods , Treatment Outcome , Bone Neoplasms/surgery , Nitrogen
2.
BMC Musculoskelet Disord ; 24(1): 139, 2023 Feb 22.
Article in English | MEDLINE | ID: mdl-36814214

ABSTRACT

BACKGROUND: Chondroblastoma (CBL) is a rare benign chondroid producing bone tumor that typically occurs in epiphysis or apophysis of growing children and young adults. Intralesional curettage is the treatment of choice, while resection is required in selected cases, even though the use of minimally invasive ablation techniques has been advocated. Authors reviewed a series of 75 CBLs with the aim of assess risk factors for local recurrence, the growth plate related complications after epiphyseal curettage and the risk of arthritis of the adjacent joint after epiphyseal curettage. METHODS: We retrospectively review 69 CBLs treated with intralesional curettage and 6 treated with resection from March 1995 to February 2020. The median age was 18.8 years (7 to 42, median 16). The site was proximal humerus in 18 cases, proximal tibia in 17, distal femur in 16, talus in 6, femur's head in 4, calcaneus in 3, acromion in 3, trochanteric region in 2, distal tibia in 2, patella in 2, supracetabular region in 1 and distal humerus in 1 patient. RESULTS: Mean follow-up was 124.2 months (24 to 322, median 116). Among patients treated with curettage, 7.3% of local recurrence was observed and 12 (17.4%) patients developed osteoarthritis of the adjacent joint. Five patients (7.3%) presented limb length discrepancy of the operated limb ranging from 0.5 to 2 cm. Recurrence free survival rate was 94.2% at 5 and 91.6% at 10 years. A mean Musculoskeletal Tumor Society (MSTS) of 29.3 points (20 to 30, median 30) was observed. CONCLUSION: More than 90% of CBLs were successfully treated with aggressive curettage but segmental resection is required in selected cases. In a relatively small proportion of cases long term complications can occur due to growth plate damage or osteoarthritis. TRIAL REGISTRATION: Retrospectively registered.


Subject(s)
Bone Neoplasms , Cartilage, Articular , Chondroblastoma , Osteoarthritis , Child , Young Adult , Humans , Adolescent , Chondroblastoma/etiology , Chondroblastoma/pathology , Chondroblastoma/surgery , Growth Plate , Cartilage, Articular/pathology , Treatment Outcome , Bone Neoplasms/surgery , Curettage/methods , Osteoarthritis/surgery , Neoplasm Recurrence, Local/surgery , Retrospective Studies
3.
Immunotherapy ; 10(12): 1033-1039, 2018 09.
Article in English | MEDLINE | ID: mdl-30185135

ABSTRACT

Administration of anti-TNFα agents has become a mainstay in the treatment of chronic inflammatory arthritis such as rheumatoid arthritis (RA) and spondyloarthritis. Adverse events, including infections and allergic reactions, have been reported. Malignancies are rare but potentially life threatening. The existence of bone tumor in those patients is very rare, only five cases of bone tumors were mentioned in juvenile idiopathic arthritis (JIA) in the literature. We describe three patients in whom bone neoplasms developed after years of anti-TNFα therapy for JIA or juvenile ankylosing spondylitis (JAS). One patient developed chondroblastoma, and the other two were diagnosed with osteosarcoma. Rheumatologists should increase their awareness of bone neoplasia in JIA or juvenile ankylosing spondylitis patients after anti-TNFα treatment.


Subject(s)
Arthritis, Juvenile/drug therapy , Bone Neoplasms/diagnosis , Chondroblastoma/diagnosis , Drug-Related Side Effects and Adverse Reactions/diagnosis , Immunotherapy/methods , Osteosarcoma/diagnosis , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab/adverse effects , Adalimumab/pharmacology , Adalimumab/therapeutic use , Adolescent , Adult , Arthritis, Juvenile/complications , Bone Neoplasms/etiology , Chondroblastoma/etiology , Etanercept/adverse effects , Etanercept/pharmacology , Etanercept/therapeutic use , Humans , Immunotherapy/adverse effects , Infliximab/adverse effects , Infliximab/pharmacology , Infliximab/therapeutic use , Male , Osteosarcoma/etiology , Young Adult
4.
Pathol Res Pract ; 214(9): 1510-1513, 2018 Sep.
Article in English | MEDLINE | ID: mdl-30100356

ABSTRACT

Cardio-facio-cutaneous syndrome (CFCS) is a rare genetic disorder characterized by craniofacial deformities and heterogeneous cardiac and cutaneous manifestations. The condition is caused by de novo activating mutations in one of four genes encoding proteins involved in the RAS-MAPK signaling pathway; specifically BRAF, MEK1, MEK2, or KRAS. Variable malignancies have been reported in patients with CFCS. Herein we report a chondroblastoma-like lesion of the skull in a 20-year-old man with a clinical diagnosis of CFCS and a long-standing history of medically intractable epilepsy. Patients with CFCS have previously been noted to have poorly-defined giant cell lesions and this may be one such example.


Subject(s)
Chondroblastoma/etiology , Ectodermal Dysplasia/complications , Failure to Thrive/complications , Heart Defects, Congenital/complications , Skull Neoplasms/etiology , Drug Resistant Epilepsy/etiology , Facies , Humans , Male , Young Adult
6.
Skeletal Radiol ; 31(2): 103-6, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11828332

ABSTRACT

A case of malignant transformation of polyostotic fibrous dysplasia into maxillary chondroblastic osteosarcoma is presented. The clinical, radiographic, CT, MR imaging features and pathological findings of polyostotic fibrous dysplasia and its malignant transformation are described. Malignant transformation of fibrous dysplasia is rare and has not previously been described in the English literature in this location in McCune-Albright syndrome and in the absence of radiation treatment.


Subject(s)
Chondroblastoma/etiology , Fibrous Dysplasia, Polyostotic/complications , Maxillary Neoplasms/etiology , Osteosarcoma/etiology , Adolescent , Chondroblastoma/diagnosis , Chondroblastoma/pathology , Fibrous Dysplasia, Polyostotic/diagnosis , Humans , Magnetic Resonance Imaging , Male , Maxillary Neoplasms/diagnosis , Maxillary Neoplasms/pathology , Osteosarcoma/diagnosis , Osteosarcoma/pathology , Tomography, X-Ray Computed
7.
In. Tommasi, Antonio Fernando. Diagnóstico em patologia bucal. Säo Paulo, Pancast, 2.ed; 1989. p.319-25, ilus.
Monography in Portuguese | LILACS, BBO - Dentistry | ID: lil-255822
8.
In. Tommasi, Antonio Fernando. Diagnóstico em patologia bucal. Säo Paulo, Artes Médicas, 1988. p.231-7, ilus.
Monography in Portuguese | LILACS, BBO - Dentistry | ID: lil-255938
10.
Am J Med ; 78(4): 669-73, 1985 Apr.
Article in English | MEDLINE | ID: mdl-2984933

ABSTRACT

Orally administered phosphate supplements are the mainstay of therapy for hypophosphatemic osteomalacia of diverse causes and are generally believed to be free from harmful side effects. Two cases are reported, however, in which long-term therapy (14 and 10 years, respectively) resulted in hypercalcemic hyperparathyroidism associated with surgically proved adenomatous hyperplasia. This complication occurred despite concomitant treatment with pharmacologic doses of vitamin D. Thus, long-term oral phosphate therapy can produce tertiary hyperparathyroidism in susceptible patients.


Subject(s)
Hypercalcemia/chemically induced , Hyperparathyroidism/chemically induced , Osteomalacia/drug therapy , Phosphates/therapeutic use , Adult , Calcitriol/therapeutic use , Chondroblastoma/etiology , Chondroblastoma/secondary , Femoral Neoplasms/etiology , Humans , Hyperparathyroidism/blood , Hypophosphatemia, Familial/etiology , Male , Middle Aged , Neoplasm Recurrence, Local , Osteomalacia/blood , Parathyroid Glands/pathology , Parathyroid Glands/surgery , Parathyroid Hormone/blood , Phosphates/blood , Vitamin D/therapeutic use
11.
Eksp Onkol ; 7(5): 37-41, 1985.
Article in Russian | MEDLINE | ID: mdl-4065017

ABSTRACT

The ultrastructure of chondroblastomas and two new ultrastructural peculiarities typical of the given form of tumours are described. Being typical but not constant these peculiarities may be an additional argument indicating that such cells may be regarded as chondroblastoma cells. The ultrastructure of these cells is similar to that of normal epiphyseal chondrocytes and differs from the ultrastructure of chondrosarcoma cells.


Subject(s)
Chondroblastoma/ultrastructure , Adolescent , Adult , Cell Nucleus/ultrastructure , Chondroblastoma/etiology , Cytoplasm/ultrastructure , Humans , Microscopy, Electron
12.
In. Tommasi, Antonio Fernando. Diagnóstico em patologia bucal. Säo Paulo, Artes Médicas, 1982. p.231-7, ilus. (BR).
Monography in Portuguese | LILACS, BBO - Dentistry | ID: lil-263461
SELECTION OF CITATIONS
SEARCH DETAIL